Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott downsizes vascular biz

This article was originally published in The Gray Sheet

Executive Summary

Abbott says it remains optimistic about prospects for its Xience everolimus-eluting coronary stent and that internal estimates of the device's potential remain unchanged despite plans to cut 1,200 manufacturing jobs from the firm's vascular products business. Initiated Dec. 4, the reductions in force reflect overcapacity due to recent increases in efficiency, as well as market conditions that include a weak U.S. drug-eluting stent sector, the company says. Abbott will close its Galway, Ireland facility with 500 employees and downsize its Temecula, Calif. facility by 700 - going from a total of about 4,700 to 4,000. The action will be completed over the next several months, according to the company. Abbott notes that it remains on track to launch Xience in the United States in the first half of 2008 following an approval recommendation from FDA's Circulatory System Devices Panel Nov. 29; the device has been available in Europe since last fall (1"The Gray Sheet" Dec. 3, 2007, p. 3). Competitors Johnson & Johnson and Boston Scientific also recently initiated downsizing actions encompassing their stent businesses to help address declining sales of the devices (2"The Gray Sheet" Oct. 22, 2007, p. 6)

You may also be interested in...



FDA Advisory Panel Cautiously Endorses Abbott Xience V Drug-Eluting Stent

FDA's Circulatory System Devices panel overwhelmingly endorsed PMA approval of Abbott's Xience V everolimus-eluting, despite reservations about its long-term safety

Boston Scientific Cuts Workforce By 13% To Help Save In ’08 H

Boston Scientific will reduce its head count by 2,300 and consolidate certain business units as part of a broader restructuring plan aimed at saving an estimated $475 million to $525 million in 2008, the firm announced Oct. 17

COVID-19 Lockdown: India Pharma Manufacturing Limps Along Amid Challenges

Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.

UsernamePublicRestriction

Register

MT025561

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel